Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis / 대한소화기학회지
The Korean Journal of Gastroenterology
; : 44-49, 2017.
Article
em En
| WPRIM
| ID: wpr-10153
Biblioteca responsável:
WPRO
ABSTRACT
Crohn's disease and ulcerative colitis are the two major types of inflammatory bowel disease, and affect mainly the gastrointestinal tract but also have extraintestinal sequelae, such as arterial and venous thromboembolism. Thromboembolic complications, particularly pulmonary thromboembolism, can be life threatening and require prompt management with anticoagulants. Conventional vitamin K antagonists have been used for the treatment of thromboembolic complications, but the development of novel oral anticoagulants has shifted the paradigm. We report a case of a 42-year-old female with ulcerative colitis who experienced an acute flare-up due to cytomegalovirus superinfection with pulmonary thromboembolism. She was treated with oral mesalamine, intravenous steroid and ganciclovir and low-molecular-weight heparin, followed by rivaroxaban, a novel oral anticoagulant. Her symptoms resolved after treatment, and no recurrence was noted during a 6-month post-treatment follow-up.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Embolia Pulmonar
/
Recidiva
/
Úlcera
/
Vitamina K
/
Doenças Inflamatórias Intestinais
/
Superinfecção
/
Colite Ulcerativa
/
Doença de Crohn
/
Ganciclovir
/
Seguimentos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article